CanWell Pharma Secures FDA IND for CAN016 ADC Trial
WOBURN, Mass., April 1, 2026 CanWell Pharma Inc. announced that the U.S. Food and Drug Administration (FDA) has granted...
AI in Healthcare Alzheimer’s Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy cGxP Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP GMP compliance Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
WOBURN, Mass., April 1, 2026 CanWell Pharma Inc. announced that the U.S. Food and Drug Administration (FDA) has granted...
NOVATO, Calif., March 30, 2026 Ultragenyx Pharmaceutical Inc. has announced that the U.S. Food and Drug Administration (FDA) has...
SUZHOU, China, March 2, 2026 XellSmart Pharmaceutical Co., Ltd. announced that it has received its fourth consecutive Investigational New...
SUZHOU, China, Feb. 15, 2026 — CStone Pharmaceuticals announced that the U.S. Food and Drug Administration has granted Investigational...
SEONGNAM, South Korea, Feb. 6, 2026 — PharmaResearch Co., Ltd. announced that the U.S. Food and Drug Administration (FDA)...
Chatham, N.J. — Nov. 24, 2025 — Tonix Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has...
Dateline Introduction Shanghai, China & Cambridge, Massachusetts — November 17, 2025 — YolTech Therapeutics has received FDA Investigational New...
